Inflammatory and Prothrombotic Biomarkers Contribute to the Persistence of Sequelae in Recovered COVID-19 Patients
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417468 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Nallely Garcia-Larragoiti und 6 weiteren Autor:innen. Beteiligte Einrichtung: División de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, M…. Hauptthemen laut MEDLINE: COVID-19, Metabolic Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Humanidades, Ciencias y Tecnologías, Universidad Michoacana de San Nicolás de Hidalgo, 320085 CONAHCYT project.
Abstract (Originalsprache)
The presence of long COVID (LC) following SARS-CoV-2 infection is a common condition that affects the quality of life of patients and represents a diagnostic challenge due to the diversity of symptoms that may coexist. We still do not have accurate information regarding the pathophysiological pathways that generate the presence of LC, and so it is important to know the inflammatory and immunothrombotic biomarker profiles and their implications in order to characterize risk subgroups and establish early therapeutic strategies. We performed the determination of inflammatory and immunothrombotic biomarkers in volunteers with previous diagnoses of SARS-CoV-2. The inflammatory biomarkers were analyzed in plasma by flow cytometry, and we analyzed the von Willebrand factor (vWF) in the plasma samples using ELISA. The clinical variables and the presence or absence of long COVID symptoms were then analyzed. IL-6, sCD40L, p-Selectin, PSGL-1, PAI-1, tPA, D-Dimer, TF, and Factor IX levels were elevated in the groups with LC, especially in the subgroup of patients with metabolic syndrome (MetS). VWF levels were found to be increased in patients with sequelae and MetS. Our results confirmed the persistence of an active immunothrombotic state, and so it is important to identify the population at risk in order to provide adequate clinical follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- División de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58060, Michoacán, Mexico.
- Centro Multidisciplinario de Estudios en Biotecnología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58060, Michoacán, Mexico.
- Hospital Regional de Morelia ISSSTE, Morelia 58300, Michoacán, Mexico.
ORCID-Profile: Nallely Garcia-Larragoiti, Martha Eva Viveros-Sandoval
Förderung
- Consejo Nacional de Humanidades, Ciencias y Tecnologías
- Universidad Michoacana de San Nicolás de Hidalgo
- 320085 CONAHCYT project
- UMNSH-CIC 2022
Zitieren
APA
Garcia-Larragoiti, N., Cano-Mendez, A., Jimenez-Vega, Y., Trujillo, M., Guzman-Cancino, P., Ambriz-Murillo, Y., & Viveros-Sandoval, M. E. (2023). Inflammatory and Prothrombotic Biomarkers Contribute to the Persistence of Sequelae in Recovered COVID-19 Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417468
Vancouver
Garcia-Larragoiti N, Cano-Mendez A, Jimenez-Vega Y, Trujillo M, Guzman-Cancino P, Ambriz-Murillo Y, et al. Inflammatory and Prothrombotic Biomarkers Contribute to the Persistence of Sequelae in Recovered COVID-19 Patients. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417468
BibTeX
@article{GarciaLarragoiti2023,
author = {Garcia-Larragoiti, Nallely and Cano-Mendez, Alan and Jimenez-Vega, Yeny and Trujillo, Mercedes and Guzman-Cancino, Patricia and Ambriz-Murillo, Yesenia and Viveros-Sandoval, Martha Eva},
title = {Inflammatory and Prothrombotic Biomarkers Contribute to the Persistence of Sequelae in Recovered COVID-19 Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417468}
}
EUVIMED